To include your compound in the COVID-19 Resource Center, submit it here.

Yondelis trabectedin: Final Phase III data

Final data from the open-label, international Phase III OVA-301 trial in 672 patients showed that 1.1 mg/m 2 Yondelis plus Doxil doxorubicin non-significantly improved median OS vs. Doxil alone (22.2 vs. 18.8 months, p=0.0835). However, a multivariate analysis of the

Read the full 405 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE